Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine-SR Open-Label Extension in MS
NCT00654927Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- Nov 2003
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dalfampridine in multiple sclerosis (MS), sponsored by Acorda Therapeutics. Started Nov 2003; status: completed.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00654927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00654927.